Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.

ABSTRACT:

Background

Radiation pneumonitis (RP) is a common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The treatment of RP needs to be improved.

Methods

NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.

Results

A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs 1.47 months, P = 

SUBMITTER: Chen G 

PROVIDER: S-EPMC12620006 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature